<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9653323</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">35460446</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">9653323</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">2490</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s00429-022-02490-1</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical information of the sample</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical information of the sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Brain tumor types</th><th align="left" rowspan="2">Statistic</th><th align="left" rowspan="2"><italic>p</italic>-value</th></tr><tr><th align="left">Low-grade gliomas</th><th align="left">High-grade gliomas</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Patients</td><td align="left">11</td><td align="left">17</td><td align="left">28</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Age (years mean, SD)</td><td align="left">41 ± 15</td><td align="left">54 ± 12</td><td align="left">49 ± 14*</td><td align="left">t(26) = 2.48</td><td align="left">0.02*</td></tr><tr><td align="left">Gender (# males)</td><td align="left">9</td><td align="left">13</td><td align="left">22</td><td align="left">χ2 = 0.11</td><td align="left">0.73</td></tr><tr><td align="left">Tumor lateralization (# Left)</td><td align="left">7</td><td align="left">8</td><td align="left">15</td><td align="left">χ2 = 0.14</td><td align="left">0.70</td></tr><tr><td align="left">Tumor WHO grade (# patients)</td><td align="left">Grade I (2), Grade II (9)</td><td align="left">Grade III (5), Grade IV (12)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">Tumor volume cm<sup>3 </sup>(mean, SD)</td><td align="left">13.7 ± 3.3</td><td align="left">40.3 ± 34.4</td><td align="left">26.7 ± 29.5*</td><td align="left">t(26) = -2.20</td><td align="left">0.037*</td></tr><tr><td align="left">Awake surgery (# patients)</td><td align="left">10</td><td align="left">10</td><td align="left">20</td><td align="left">χ2 = 1.62</td><td align="left">0.20</td></tr><tr><td align="left">IDH mutation (# patients)</td><td align="left">3</td><td align="left">3</td><td align="left">6</td><td align="left">χ2 = 0.36, NA</td><td align="left">0.54, NA</td></tr><tr><td align="left">MGMT methylation (# patients)</td><td align="left">0</td><td align="left">6</td><td align="left">6</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Extent of resection % (mean, SD)</td><td align="left">91.82 ± 11.32</td><td align="left">96,68 ± 9.64</td><td align="left">94.77 ± 10.41</td><td align="left">Z(26) = 1.76</td><td align="left">0.08</td></tr><tr><td align="left">Radiotherapy [(# patients (weeks mean, SD)]</td><td align="left">0</td><td align="left">12 (5.75 ± 0.87)</td><td align="left">12</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Proton therapy [(# patients (weeks mean, SD)]</td><td align="left">0</td><td align="left">5 (6 ± 0)</td><td align="left">5</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Chemotherapy [(# patients (months mean, SD)]</td><td align="left">0</td><td align="left">17 (10.71 ± 3.35)</td><td align="left">17</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Tumor overlap hubs (mean %, SD %)</td><td align="left">1.6 ± 2.2</td><td align="left">1.8 ± 2.4</td><td align="left">1.4 ± 2.1</td><td align="left">t(26) = 1.04</td><td align="left">0.30</td></tr><tr><td align="left">Tumor overlap no-hubs (mean %, SD %)</td><td align="left">2.1 ± 1.9</td><td align="left">2.3 ± 1.9</td><td align="left">1.7 ± 1.9*</td><td align="left">t(26) = 2.23</td><td align="left">0.034*</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>-value &lt; 0.05</p><p><italic>SD</italic> Standard deviation, <italic>WHO</italic> World Health Organization, <italic>IDH</italic> Isocitrate dehydrogenase, <italic>MGMT</italic> O6-Methylguanine-DNA-methyltransferase</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical information of the sample</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Brain tumor types</th><th align="left" rowspan="2">Statistic</th><th align="left" rowspan="2">p-value</th></tr><tr><th align="left">Low-grade gliomas</th><th align="left">High-grade gliomas</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Patients</td><td align="left">11</td><td align="left">17</td><td align="left">28</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Age (years mean, SD)</td><td align="left">41 ± 15</td><td align="left">54 ± 12</td><td align="left">49 ± 14*</td><td align="left">t(26) = 2.48</td><td align="left">0.02*</td></tr><tr><td align="left">Gender (# males)</td><td align="left">9</td><td align="left">13</td><td align="left">22</td><td align="left">χ2 = 0.11</td><td align="left">0.73</td></tr><tr><td align="left">Tumor lateralization (# Left)</td><td align="left">7</td><td align="left">8</td><td align="left">15</td><td align="left">χ2 = 0.14</td><td align="left">0.70</td></tr><tr><td align="left">Tumor WHO grade (# patients)</td><td align="left">Grade I (2), Grade II (9)</td><td align="left">Grade III (5), Grade IV (12)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">Tumor volume cm3 (mean, SD)</td><td align="left">13.7 ± 3.3</td><td align="left">40.3 ± 34.4</td><td align="left">26.7 ± 29.5*</td><td align="left">t(26) = -2.20</td><td align="left">0.037*</td></tr><tr><td align="left">Awake surgery (# patients)</td><td align="left">10</td><td align="left">10</td><td align="left">20</td><td align="left">χ2 = 1.62</td><td align="left">0.20</td></tr><tr><td align="left">IDH mutation (# patients)</td><td align="left">3</td><td align="left">3</td><td align="left">6</td><td align="left">χ2 = 0.36, NA</td><td align="left">0.54, NA</td></tr><tr><td align="left">MGMT methylation (# patients)</td><td align="left">0</td><td align="left">6</td><td align="left">6</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Extent of resection % (mean, SD)</td><td align="left">91.82 ± 11.32</td><td align="left">96,68 ± 9.64</td><td align="left">94.77 ± 10.41</td><td align="left">Z(26) = 1.76</td><td align="left">0.08</td></tr><tr><td align="left">Radiotherapy [(# patients (weeks mean, SD)]</td><td align="left">0</td><td align="left">12 (5.75 ± 0.87)</td><td align="left">12</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Proton therapy [(# patients (weeks mean, SD)]</td><td align="left">0</td><td align="left">5 (6 ± 0)</td><td align="left">5</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Chemotherapy [(# patients (months mean, SD)]</td><td align="left">0</td><td align="left">17 (10.71 ± 3.35)</td><td align="left">17</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Tumor overlap hubs (mean %, SD %)</td><td align="left">1.6 ± 2.2</td><td align="left">1.8 ± 2.4</td><td align="left">1.4 ± 2.1</td><td align="left">t(26) = 1.04</td><td align="left">0.30</td></tr><tr><td align="left">Tumor overlap no-hubs (mean %, SD %)</td><td align="left">2.1 ± 1.9</td><td align="left">2.3 ± 1.9</td><td align="left">1.7 ± 1.9*</td><td align="left">t(26) = 2.23</td><td align="left">0.034*</td></tr></tbody></table></div>*p-value &lt; 0.05SD Standard deviation, WHO World Health Organization, IDH Isocitrate dehydrogenase, MGMT O6-Methylguanine-DNA-methyltransferase</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Functional connectivity profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection, while high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: time (a positive effect means longitudinal connectivity increases regardless of tumor grade and lateralization), time ×tumor grade interaction (a positive effect means that longitudinal connectivity increases faster in LGG relative to HGG, regardless of lateralization) and time ×tumor lateralization (positive means that longitudinal connectivity in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted with age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Functional connectivity profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection, while high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: <italic>time</italic> (a positive effect means longitudinal connectivity increases regardless of tumor grade and lateralization), <italic>time</italic> ×<italic>tumor grade</italic> interaction (a positive effect means that longitudinal connectivity increases faster in LGG relative to HGG, regardless of lateralization) and <italic>time</italic> ×<italic>tumor lateralization</italic> (positive means that longitudinal connectivity in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted with age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (<italic>p &lt; </italic>0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="3">Predictors [Estimate β, <italic>p</italic>-value, Cohen’s d if significant]</th><th align="left">Random effects</th></tr><tr><th align="left">Time</th><th align="left">Time × tumor grade</th><th align="left">Time × tumor lateralization</th><th align="left">σ<sup>2</sup></th></tr></thead><tbody><tr><td align="left">Within default -mode network</td><td align="left">[0.003, 0.54]</td><td align="left">[0.00002, 0.01, 0.001]*</td><td align="left">[0.006, 0.001, 0.28]*</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within fronto-parietal network</td><td align="left">[0.006, 0.28]</td><td align="left">[ – 0.01, 0.63]</td><td align="left">[ – 0.003, 0.11]</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within hubs</td><td align="left">[0.002, 0.68]</td><td align="left">[ – 0.003,  – 0.15]</td><td align="left">[0.005, 0.0004, 0.29]*</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within no-hubs</td><td align="left">[ – 0.0006, 0.44]</td><td align="left">[0.0010, 0.71]</td><td align="left">[ – 0.001, 0.004,  – 0.30]*</td><td char="." align="char">0.0004</td></tr><tr><td align="left">Between hubs-no-hubs</td><td align="left">[0.0004, 0.75]</td><td align="left">[ – 0.001, 0.65]</td><td align="left">[0.0023, 0.005, 0.40]*</td><td char="." align="char">0.0001</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>-value<sub>FDR</sub> &lt; 0.05</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Functional connectivity profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection, while high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: time (a positive effect means longitudinal connectivity increases regardless of tumor grade and lateralization), time ×tumor grade interaction (a positive effect means that longitudinal connectivity increases faster in LGG relative to HGG, regardless of lateralization) and time ×tumor lateralization (positive means that longitudinal connectivity in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted with age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="3">Predictors [Estimate β, p-value, Cohen’s d if significant]</th><th align="left">Random effects</th></tr><tr><th align="left">Time</th><th align="left">Time × tumor grade</th><th align="left">Time × tumor lateralization</th><th align="left">σ2</th></tr></thead><tbody><tr><td align="left">Within default -mode network</td><td align="left">[0.003, 0.54]</td><td align="left">[0.00002, 0.01, 0.001]*</td><td align="left">[0.006, 0.001, 0.28]*</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within fronto-parietal network</td><td align="left">[0.006, 0.28]</td><td align="left">[ – 0.01, 0.63]</td><td align="left">[ – 0.003, 0.11]</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within hubs</td><td align="left">[0.002, 0.68]</td><td align="left">[ – 0.003,  – 0.15]</td><td align="left">[0.005, 0.0004, 0.29]*</td><td char="." align="char">0.01</td></tr><tr><td align="left">Within no-hubs</td><td align="left">[ – 0.0006, 0.44]</td><td align="left">[0.0010, 0.71]</td><td align="left">[ – 0.001, 0.004,  – 0.30]*</td><td char="." align="char">0.0004</td></tr><tr><td align="left">Between hubs-no-hubs</td><td align="left">[0.0004, 0.75]</td><td align="left">[ – 0.001, 0.65]</td><td align="left">[0.0023, 0.005, 0.40]*</td><td char="." align="char">0.0001</td></tr></tbody></table></div>*p-valueFDR &lt; 0.05</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: time (a positive effect means that, longitudinally, the neuropsychological measure increases regardless of tumor grade and lateralization), time × tumor grade interaction (a positive effect means that, longitudinally, the neuropsychological measure increases faster in LGG relative to HGG, regardless of lateralization) and time × tumor lateralization (positive means that, longitudinally, the neuropsychological measure in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect size and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3"><label>Table 3</label><caption><p>Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: <italic>time</italic> (a positive effect means that, longitudinally, the neuropsychological measure increases regardless of tumor grade and lateralization), <italic>time</italic> × <italic>tumor grade</italic> interaction (a positive effect means that, longitudinally, the neuropsychological measure increases faster in LGG relative to HGG, regardless of lateralization) and <italic>time</italic> × <italic>tumor lateralization</italic> (positive means that, longitudinally, the neuropsychological measure in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (<italic>p</italic> &lt; 0.05) fixed effects are emphasized in bold with their respective effect size and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="3">Predictors [Estimate β, <italic>P</italic>-value, Cohen’s d (if significant)]</th><th align="left">Random effects</th></tr><tr><th align="left">Time</th><th align="left">Time × tumor grade</th><th align="left">Time × tumor lateralization</th><th align="left">σ<sup>2</sup></th></tr></thead><tbody><tr><td align="left">Rey complex figure delayed reproduction</td><td align="left">[0.75, 0.0025, 0.94]*</td><td align="left">[ – 0.26, 0.51]</td><td align="left">[ – 0.26, 0.45]</td><td char="." align="char">25.81</td></tr><tr><td align="left">Rey’s 15-word list delayed recall</td><td align="left">[ – 0.07, 0.432]</td><td align="left">[ – 0.14, 0.12]</td><td align="left">[0.18, 0.032, 0.43]</td><td char="." align="char">3.95</td></tr><tr><td align="left">Picture-naming test</td><td align="left">[0.14, 0.15]</td><td align="left">[ – 0.09, 0.0333,  – 0.22]</td><td align="left">[0.08, 0.74]</td><td char="." align="char">3.94</td></tr><tr><td align="left">Corsi span</td><td align="left">[ – 0.04, 0.15]</td><td align="left">[0.07, 0.0435, 0.57]</td><td align="left">[0.06, 0.638]</td><td char="." align="char">0.34</td></tr><tr><td align="left">Semantic fluency</td><td align="left">[ – 0.55, 0.046,  – 0.63]</td><td align="left">[0.42, 0.66]</td><td align="left">[0.82, 0.17]</td><td char="." align="char">31.93</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>-value<sub>FDR</sub> &lt; 0.05</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated with only surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included the following main predictors: time (a positive effect means that, longitudinally, the neuropsychological measure increases regardless of tumor grade and lateralization), time × tumor grade interaction (a positive effect means that, longitudinally, the neuropsychological measure increases faster in LGG relative to HGG, regardless of lateralization) and time × tumor lateralization (positive means that, longitudinally, the neuropsychological measure in left-lateralized glioma increases faster than in right-lateralized glioma, regardless of tumor grade). The model was adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation, and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect size and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="3">Predictors [Estimate β, P-value, Cohen’s d (if significant)]</th><th align="left">Random effects</th></tr><tr><th align="left">Time</th><th align="left">Time × tumor grade</th><th align="left">Time × tumor lateralization</th><th align="left">σ2</th></tr></thead><tbody><tr><td align="left">Rey complex figure delayed reproduction</td><td align="left">[0.75, 0.0025, 0.94]*</td><td align="left">[ – 0.26, 0.51]</td><td align="left">[ – 0.26, 0.45]</td><td char="." align="char">25.81</td></tr><tr><td align="left">Rey’s 15-word list delayed recall</td><td align="left">[ – 0.07, 0.432]</td><td align="left">[ – 0.14, 0.12]</td><td align="left">[0.18, 0.032, 0.43]</td><td char="." align="char">3.95</td></tr><tr><td align="left">Picture-naming test</td><td align="left">[0.14, 0.15]</td><td align="left">[ – 0.09, 0.0333,  – 0.22]</td><td align="left">[0.08, 0.74]</td><td char="." align="char">3.94</td></tr><tr><td align="left">Corsi span</td><td align="left">[ – 0.04, 0.15]</td><td align="left">[0.07, 0.0435, 0.57]</td><td align="left">[0.06, 0.638]</td><td char="." align="char">0.34</td></tr><tr><td align="left">Semantic fluency</td><td align="left">[ – 0.55, 0.046,  – 0.63]</td><td align="left">[0.42, 0.66]</td><td align="left">[0.82, 0.17]</td><td char="." align="char">31.93</td></tr></tbody></table></div>*p-valueFDR &lt; 0.05</transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) associated with Functional Connectivity (FC) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated only with surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included time and time × FC metrics (within default mode network (DMN) FC, within fronto-parietal network (FTPN) FC, within no-hubs FC, between hubs and no-hubs FC) interactions as main predictors of interest (a positive effect means longitudinal neuropsychological measure increases with the spatial connectivity measure regardless of tumor grade and lateralization) adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab4"><label>Table 4</label><caption><p>Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) associated with Functional Connectivity (FC) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated only with surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included time and <italic>time</italic> × <italic>FC metrics</italic> (within default mode network (DMN) FC, within fronto-parietal network (FTPN) FC, within <italic>no-hubs</italic> FC, between <italic>hubs</italic> and <italic>no-hubs</italic> FC) interactions as main predictors of interest (a positive effect means longitudinal neuropsychological measure increases with the spatial connectivity measure regardless of tumor grade and lateralization) adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation and tumor WHO grade as nuisance variables. Significant (<italic>p</italic> &lt; 0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="4">Predictors [Estimate β, <italic>P</italic>-value, Cohen’s d (if significant)]</th><th align="left">Random effects</th></tr><tr><th align="left">Time ×  within DMN FC</th><th align="left">Time × within FTPN FC</th><th align="left">Time × within no-hubs FC</th><th align="left">TIME × between hubs-no-hubs FC</th><th align="left">σ<sup>2</sup></th></tr></thead><tbody><tr><td align="left">Rey complex figure delayed reproduction</td><td align="left">[ – 0.85, 0.08]</td><td align="left">[1.28, 0.66]</td><td align="left">[49.7, 0.035, 0.36]</td><td align="left">[20.16, 0.34]</td><td char="." align="char">21.33</td></tr><tr><td align="left">Digit span</td><td align="left">[0.32, 0.008, 0.36]*</td><td align="left">[0.38, 0.25]</td><td align="left">[12.9, 0.099]</td><td align="left">[5.71, 0.07]</td><td char="." align="char">0.38</td></tr><tr><td align="left">Picture-naming test</td><td align="left">[ – 0.88, 0.77]</td><td align="left">[0.30, 0.35]</td><td align="left">[2.42, 0.23]</td><td align="left">[10.1, 0.0083, 0.39]*</td><td char="." align="char">4.13</td></tr><tr><td align="left">Trial-making test A</td><td align="left">[ – 12.75, 0.016,  – 1.16]*</td><td align="left">[ – 2.80, 0.0007,  – 0.30]*</td><td align="left">[ – 163.35, 0.28]</td><td align="left">[ – 14.51, 0.12]</td><td char="." align="char">61.77</td></tr><tr><td align="left">Trial-making test B</td><td align="left">[ – 25.90, 0.019,  – 0.63]*</td><td align="left">[ – 20.20, 0.0425,  – 0.57]</td><td align="left">[ – 504.97, 0.09]</td><td align="left">[ – 157.10, 0.12]</td><td char="." align="char">831.10</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>-value<sub>FDR</sub> &lt; 0.05</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Neuropsychological profile showing significant effects revealed by a linear mixed model of longitudinal changes (baseline, 1–3-, 3–6-, 6–9-, 9–15-month follow-ups) associated with Functional Connectivity (FC) in brain tumor patients stratified into two groups (low-grade gliomas (LGG) correspond to gliomas treated only with surgical resection and high-grade gliomas (HGG) correspond to gliomas treated with surgical resection in combination with radiotherapy and/or chemotherapy). The model included time and time × FC metrics (within default mode network (DMN) FC, within fronto-parietal network (FTPN) FC, within no-hubs FC, between hubs and no-hubs FC) interactions as main predictors of interest (a positive effect means longitudinal neuropsychological measure increases with the spatial connectivity measure regardless of tumor grade and lateralization) adjusted by age, sex, baseline tumor volume, IDH mutation, tumor methylation and tumor WHO grade as nuisance variables. Significant (p &lt; 0.05) fixed effects are emphasized in bold with their respective effect sizes and an asterisk if the effect survives FDR correction across different models of the same cognitive domain</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Response</th><th align="left" colspan="4">Predictors [Estimate β, P-value, Cohen’s d (if significant)]</th><th align="left">Random effects</th></tr><tr><th align="left">Time ×  within DMN FC</th><th align="left">Time × within FTPN FC</th><th align="left">Time × within no-hubs FC</th><th align="left">TIME × between hubs-no-hubs FC</th><th align="left">σ2</th></tr></thead><tbody><tr><td align="left">Rey complex figure delayed reproduction</td><td align="left">[ – 0.85, 0.08]</td><td align="left">[1.28, 0.66]</td><td align="left">[49.7, 0.035, 0.36]</td><td align="left">[20.16, 0.34]</td><td char="." align="char">21.33</td></tr><tr><td align="left">Digit span</td><td align="left">[0.32, 0.008, 0.36]*</td><td align="left">[0.38, 0.25]</td><td align="left">[12.9, 0.099]</td><td align="left">[5.71, 0.07]</td><td char="." align="char">0.38</td></tr><tr><td align="left">Picture-naming test</td><td align="left">[ – 0.88, 0.77]</td><td align="left">[0.30, 0.35]</td><td align="left">[2.42, 0.23]</td><td align="left">[10.1, 0.0083, 0.39]*</td><td char="." align="char">4.13</td></tr><tr><td align="left">Trial-making test A</td><td align="left">[ – 12.75, 0.016,  – 1.16]*</td><td align="left">[ – 2.80, 0.0007,  – 0.30]*</td><td align="left">[ – 163.35, 0.28]</td><td align="left">[ – 14.51, 0.12]</td><td char="." align="char">61.77</td></tr><tr><td align="left">Trial-making test B</td><td align="left">[ – 25.90, 0.019,  – 0.63]*</td><td align="left">[ – 20.20, 0.0425,  – 0.57]</td><td align="left">[ – 504.97, 0.09]</td><td align="left">[ – 157.10, 0.12]</td><td char="." align="char">831.10</td></tr></tbody></table></div>*p-valueFDR &lt; 0.05</transformed-table></extracted-table></extracted-tables-set>